Cardiology

Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy.



Icon for Elsevier Science Related Articles

Non-viral reprogramming and induced pluripotent stem cells for cardiovascular therapy.

Differentiation. 2020 Jan 10;112:58-66

Authors: Panda A, Gurusamy N, Rajasingh S, Carter HK, Thomas EL, Rajasingh J

Abstract
Despite significant effort devoted to developing new treatments and procedures, cardiac disease is still one of the leading causes of death in the world. The loss of myocytes due to ischemic injury remains a major therapeutic challenge. However, cell-based therapy to repair the injured heart has shown significant promise in basic and translation research and in clinical trials. Embryonic stem cells have been successfully used to improve cardiac outcomes. Unfortunately, treatment with these cells is complicated by ethical and legal issues. Recent progress in developing induced pluripotent stem cells (iPSCs) using non-viral vectors has made it possible to derive cardiomyocytes for therapy. This review will focus on these non-integration-based approaches for reprogramming and their therapeutic advantages for cardiovascular medicine.

PMID: 31954271 [PubMed – as supplied by publisher]

Source link





Related posts

Intra-aortic balloon pump experience: a single center study comparing with and without sheath insertion.

Newsemia

What causes heart disease – part 59

Newsemia

Revised Equation May Improve Accuracy of Cardiovascular Disease Risk Estimates

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy